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S y An explant culture technique was used to culture normal urothelium from patients with muscle-
invasive bladder cancer (transitional cel carioa TCC) (n = 11) and from non-tumour-bering patients
(n = 60). Cell cates were amined for expon of p53 using the monockoal antibody p53-240. There
was a all nt inase n p53 expression m normal urothelial cel cultures from patients with
TCC (P<0.0005). Normal urotheial ctures from patients with TCC also showed more rapid prolferation in
vitro when compared with non-tumour-baring patints (P<0.0005). A subgroup of non-tumour-bearing
patients (n = 14) showed >5% ofcells exprssng p53. p53 expr in this subgroup was found to correlate
with cell prolifation in vitro (x2 = 0.766). None of these urothelial specimens was observed to express p53
when paraffin-embedded prepaatios were stained with p53-D07 antibody prior to culture. The rate of
cellular proliferation this subgroup did not differ from that of normal urothelium from TCC patenmts.
Twenty-two paaffin-embedded, mu e-invasive TCC specimens were also evaluated for p53 expression
p53-D07. The exesson of p53 in these tumours did not differ from that obsered in normal urotheial cel
clltures from patets with TCC (P = 0.26). This study identifies an overession ofp53 in normal urothehal
cells from patients with TCC and in proferating cutures from a signiant subgroup of patients without
malinant dise. Increased p53 m normal cutured cells from patients with bladdr
canocr implie a global chang in the nisms controlling urotheial cell division This may represent an
early step in the pathway to carc.ogenesi
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Wild-type p53 protein is known to have a signcant role in
mgulating cell growth and protecting against carcinogenesis
(Hollstein, 1991; Kasten et al., 1991; Lane, 1992). Accumula-
tion of the protein in tissues and cells indicates loss of the
tumour-suppressor function and may occur as a result of a
mutation in the gene or as a result of post-translational
modifications (Werness et al., 1990; Furihata, 1993). The
protein has been shown to be overexpressed by many
tumours, including breast, colon, gastric, hepatocellular and
transitional cell carcinoma (TCC) (Harris and Hollstein,
1993; Spruck et al., 1993). Despite the widespread expression
of abnormal levels of p53 in human tumours, little is known
about the expression of the protein in dysplastic or premalig-
nant conditions. Most studies have concentrated on the
expression of the protein in frank carcinoma (Harris and
Hollstein, 1993) or in normal tissues experimentally exposed
to carcinogens (Petersn, 1993; Jones et al., 1994; Mothersill
et al., 1994).
TCC is commonly multifocal and fits the clal model of
field change in which malignant transformation represents
the final stage in a multistep pathway. There is conflicting
evidence regarding when p53 mutations occur. Sidransky et
al. (1991), Wright et al. (1991), Fujimoto et al. (1992),
Habuchi et al. (1992), Esrig et al. (1993), Lipponen (1993)
and Sarkis et al. (1993) have all correlated p53 overexpres-
sion with invasive phenotype and progression of TCC, but
whether the p53 mutation occurs early or late in the process
of progression is not clear. Recent evidence from our group
(Mothersill et al., 1994) shows induction in urotheial cultures
of p53 overexpression by radiation and/or nitrosamines,
which are both known carcnogenic agents for bladder.
Spruck et al. (1993) have shown a distinct pattern of p53
mutations in bladder cancers from smokers, which might also
suggest that in smokers, at least, p53 mutations occur as an
early event The aim of this study was to determine whether
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p53 overexpression occurred in normal urothelial tissues
from patients with TCC and to compare these patients with a
non-cancer-bearing group. Since the protein expression is
strongly linked with proliferation (Harris and Hollstein,
1993), tissues were examined for expression of the protein
while growing in vitro as well as in formalin-fixed paraffin-
embedded sections.
Materiab aud ethod
Normal urothelium was obtained from patients undergoing
reconstructive surgery for benign disease. None of these
patients had any malignant disease or other condition involv-
ing hyperproliferation of the urothelium. 'Normal' uro-
thelium was also obtained from the resected ureters of
patients undergoing cystectomy for muscle-invasive TCC. In
these cases the urothelium was obtained from an area remote
from the site of tumour. All specimens of urothelium were
free of dysplasia and caranoma on histological examination.
No patient included in the study had previously been treated
with radiotherapy. All tumours were grade 2 or 3 and, at the
time of recovery of normal urothelium, had a local stage of
T2 or greater.
TLssues were stored at 4-C prior to being transported to
the laboratory and processed as soon as possible after retri-
eval. All specimens were dissted free of fat and intact
ureters were opened longitudinally. Using a purpose-built
cutting template, 2 mm2 sections of urothelium were obtain-
ed. These were incubated in a calcium- and magnesium-free,
balanced salt solution (Gibco, Biocult, UK), containing 0.1%
(w/v) trypsin and 10mgml1' type IV collagnase (Sigma,
London, UK) and incubated at 37C for 1 h. At the end of
this period, the fragments of urothelium were shaken
vigorously and then allowed to settle. The supernatant fluid
containing parally digested fibrous tissue as discarded and
the fragments of urotheium were individually transferred to
25 cm2 tissue culture flasks (Nunclon, Delta, Denmark) con-
taining 2 ml of RPMI-1640 supplemented as previously des-p53 e iessun hi n cds
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cribed (Mothersill et al., 1988) with 14% fetal calf serum. 7%
horse serum (Gibco Biocult), 1 #ig ml-' hydrocortisone
(Sigma) and 100 mIU ml- insulin (Novonordisk Actrapid).
The use of an explant technique rather than a monolayer
culture method permitted large numbers of cultures (typically
70-80) to be set up from small specimens, although the total
number of cultures was obviously dependent on the size of
the initial specimen obtained.
Immunohistochemistrv and histology
All bladder cancer specimens and representative samples of
urothelium from both groups of normal urothelium were
fixed in formalin and paraffin embedded prior to sectioning.
Tissue cultures were fixed in formalin for 1 h after 14 days'
growth in tissue culture. They were transferred to phosphate-
buffered saline (PBS) and stored at 4'C prior to immuno-
chemical analysis. The primary antibodies used against p53
were p53-D07 (Novocastra) at a dilution of 1:50 and p53-240
(Novocastra) at a dilution of 1:20. p53-D07 is a murine
monoclonal antibody that is effective in paraffin sections and
recognises both wild and mutant variants of p53. It has been
shown, however, that detectable p53 in paraffin sections is
always a stable form of the protein since the wild-type pro-
tein does not survive processing (Lane and Benchimol, 1990).
p53-240 is also a mouse monoclonal antibody; however, it
can only be used on non-paraffin-embedded tissue and is
specific for the stable conformation of the protein (Gannon
et al., 1990). None of the antibodies are capable of identify-
ing 100% of tissues with a proven (SSCP) mutation (Lamkin
et al., 1994). Positive and immunocytochemical analysis was
therefore taken to mean expression of the non-functional or
stable form of the p53 protein'.
Binding of the pnrmary antibody was detected using the
Vectastain ABC kit (Vector Laboratonres. Burlingame, CA,
USA) with diaminobenzidine as the colour detection system
(Hsu et al., 1981). Cultures and sections were counterstained
with Harris haematoxylin. p53-D07 was used as the primary
antibody on all paraffin-embedded material. A paraffin-
embedded breast cancer specimen known to express p53 was
used as a positive control. The HaCAT cell line, known to
express mutant p53 owing to a mutation on one allele of
chromosome 17 and a deletion on the other in the p53
region, was used as a positive control for p53-240. This
antibody was used to detect p53 in formalin-fixed tissue
cultures. Cultures or paraffin sections which had been treated
with all reagents, except the primary antibody, served as
negative controls for both antibodies. Representative cultures
were screened using an anti-cytokeratin antibody (pan-
cytokeratin, Amersham, UK) to confirm that the cultured
cells were epithelial rather than stromal.
Quantification and statistical analysis
Growth was measured after 14 days in tissue culture by
determining the number of 1 mm2 units covered by the out-
growth (excluding the original explant). The total cell
number was determined by calculating the mean cell number
in ten random 1 mm2 areas and multiplying this by the area
of the outgrowth measured in mm-. Differential counts to
determine the percentage postive cells were made by counting
positive cells and total cell numbers along transects drawn
across the outgrowth. By using percentage positive as
opposed to total positive, it was possible to compare cultures
from patients with different growth.
Results are presented as the cell number in each tissue
culture after 14 days and the percentage of positive cells in
each culture, with the standard error of the mean (s.e.m.) in
parentheses. Each measurement was repeated on at least
three (normally five) replicate cultures from each patient.
Results
Figure la shows the typical appearance of a 14-day-old
urothelial culture with low (<5% of cells) p53 expression.
a
b
Figure 1 a. Fourteen-day-old urothelial culture from a patient
with low expression of p53. b. Fourteen-day-old urothelial culture
from a patient with high expression of p53.
Figure lb shows a similar culture from a high p53 expression
patient. The morphological appearance of both cultures is
similar. Figure 2 shows the total cell number present in tissue
cultures from each patient after 14 days. for both normal
urothelial specimens obtained from patients with transitional
cell carcinoma (n = 11) and those obtained from tumour-free
patients (n = 60).
There is considerable variation between individual
patients within each group. The mean number of cells per
tissue culture for tumour-free patients was 4.28 ± 0.5 x I0W.
The mean number of cells for normal urothelial cultures
from patients with transitional cell carcinomas was
8.67 ± 1.6 x 104. This difference in cell growth was found to
be significant (P< 0.0005). The mean standard error with
replicate cultures from the same patient was 3.8 ± 0.210%.
Figure 3 shows the percentage of cells in each tissue cul-
ture. from each of the two groups. which stained positive for
p53 with the antibody p53-240. The mean percentage positive
p53 cells for patients in the tumour-free group was 13.5 +
3.10%. The mean percentage positive p53 cells for patients in
the TCC group was 46.4 ± 10.4%. The expression of p53 was
significantly greater in cell cultures from patients with TCC
(P<0.0005). Standard errors within replicate cultures were
5.3 ± 0.8% of the mean for second readers of the same
culture and 10.9 ± 2.3% of the mean for different cultures
within the same tissue.
A subgroup of tumour-free patients was found to express
> 5% cells positive for p53 following tissue culture. These
were shown to be statistical outliers using Grubb's test. The
mean percentage positive p53 cells for patients in this sub-
group of tumour-free patients was 50.7 ± 6.8%. This did notp53 ** i ndhuio cub
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Figwe 2 Cell numbers after 14 days' tissue culture for normal
urothelial specimens from tumour-bearing (n = 11) and tumour-
free (n = 60) patients. P<0.0005, d.f. = 69. The medians and
interquartiles are indicated on the graph.
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Figwe 3 Percentage of normal urotheial cells stained positive
for p53 protein following 14 days in tissue culture from tumour-
bearing (n =II) and tumour-free (n = 60) patients. P<0.0005,
d.f. = 69. The medians and interquarties are indicated on the
graph.
differ significantly from the expression of p53 observed in
normal urothelial cell cultures in the TCC group (P = 0.688).
The mean cell number after 14 days' tissue culture for this
group was 6.9 ± 1.0 x I04. This rate of cell growth did not
differ significantly from that of normal urothelial cell cultures
in the TCC group (P = 0.155), but was significantly different
from the normal culture group with p53 expression <5%
(P<0.001). The percentage of positive p53 cells in this sub-
group showed a correlation (r2 = 0.76) with total cell number
after 14 days' tissue culture (see Figure 4).
All specimens were initially evaluated for p53 expression
using the p53-D07 antibody on paraffin-embedded tissue.
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Fie 5 Percentage of cells staining positive for p53 in paraffin-
fixed, muscle-invasive TCC (n = 22) and normal urothehal cell
cultures from TCC patients (n = 11). P<0.2632, d.f. = 31. The
medians and interquarties are indicated on the graph.
None of the specimens from tumour-free patients were found
to express p53 prior to tissue culture. Paraffin-embedded
specimens of all normal urothelial specimens from TCC
patients were also examined for p53 expression prior to tissue
culture. The mean percentage positive p53 cells for normal
urothelial samples from patients with TCC was 28.2 ± 6.1%.
This expression was compared with that found following cell
culture of specimens from the same patients in a paired
Student t-test and was not found to differ significantly
(P = 0.1916). Sections from 22 paraffin-embedded, muscle-
invasive bladder cancers were also assessed for p53 expres-
sion using the p53-D07 antibody. These results are shown in
Figure 5 and the expression of p53 in cultured normal uro-
thelial specimens from patients with TCC is shown for com-
parison. The mean percentage positive cells for this group
was 34.1 ± 3.8%. The expression of p53 in this group of
tumours did not differ significantly from cultures of
normal urothelium from patients with bladder carcinoma
(P = 0.2632) or from paraffin-embedded specimens of nor-
mal urothelium from TCC patients (P = 0.398).
Eiscussion
p53 has been identified as having a pivotal role in human
carcinogenesis (Harris and Hollstein, 1993). This study was
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aimed at confirming the overexpression of p53 in TCC
observed by others (Sidransky et al., 1991; Fujimoto et al.,
1992) and determining if this overexpression of p53 could
also be found in normal urothelium from patients with TCC.
This finding would support an early involvement of p53
malfinction in premalignant urothelium and a 'field change'
model for TCC. The results for staining of 22 invasive
tumours with p53-D07 are similar to those of Wright et al.
(1991), who found that 64% (n = 33) of invasive tumours
stained moderately or strongly positive with PAb 240 or PAb
1801. The use of an arbitrary scale for staining intensity in
Wright's study prevents a direct comparison with our results.
p53-D07 was used to stain for p53 in the studies of paraffin-
embedded invasive TCC and normal urothelium prior to
culture. This antibody detects both wild and mutant confor-
mations of the protein; however, expression in paraffin-
embedded tissue is thought to be exclusively due to the
mutated conformation of the protein (Lane and Benchimol,
1990). p53 overexpression in TCC has been shown to arise
from genetic mutation rather than post-translational effects.
The status of p53 protein expression in premalgnant
urothelium is unclear but, given the current views on the role
of p53 control of growth, DNA damage response and apop-
tosis (reviewed in Cohen, 1993), it would seem logical that
alterations in p53 protein function as opposed to underlying
gene sequence could be expected at an early stage of car-
cinogenesis.
The results presented in this paper inicate that p53 over-
expression is found in normal urothelium in patients with
invasive TCC. Since specimens were taken from sites remote
from the carcinoma (usually the ureters from cystectomy
patients) and screened histologically for evidence of car-
cinoma or dysplasia, it is unlikely that the observed expres-
sion ofp53 was due to the inadvertent inclusion ofmalignant
cells in the explant specimen. The results, therefore, strongly
support a field change model for TCC rather than a clonal
model since it is hard to conceive of successful implantation
of malignant tumour clones throughout every area of the
urothelium accounting for 20-50% of cells in those areas,
without then having any histologically recognisable or
phenotypic changes. Specimens of normal urothelium from
patients with invasive TCC were assessed for expression of
p53 with both p53-D07, in intact tissue, and p53-240 follow-
ing cell culture of specimens. While the expression of the
protein was substantially higher following cell culture (mean
percentage positive cells 46.4% vs 28.2%), this difference was
not significant when analysed using a paired Student t-test
(P = 0.1916). There was no correlation between p53 expres-
sion and either stage or grade of the primary tumour.
This difference in expression between the two methods is
not surprising since the two antibodies are directed against
different epitopes. The cell cycle-dependent expression of p53
would also be expected to lead to detection ofhigher levels in
growing cultures as opposed to differentiated tissue.
p53-positive cells appeared to have an enhanced growth
rate and should consequently be present in higher numbers
following tissue culture. None of the 60 specimens from
tumour-free patients was found to express p53 when examin-
ed prior to culture with p53-D07, yet 23% showed >55% of
cells positive when stained with p53-240 following tissue
culture. This may be due to a growth advantage since the
percentage of cells positive for p53 showed a linear correla-
tion with growth in this subset of normal cultures. A similar
relationship between cell growth in tissue culture and p53
expression was not observed in cell cultures from tumour-
bearing patients, however the rate of cell growth was
significantly higher in this group and conditions in vitro or
the natural proliferation capacity of the cells may have
limited cell growth.
The presence of p53 protein in tumour-free cell cultures,
but not in the corresponding paraffin-embedded specimens,
might be accounted for by clonal expansion of a small
number of p53-positive cells in the orginal explant. This is,
however, unlikely because there was no evidence in the cul-
tures or sections of clonal expression of p53. It is also
difficult to see how a 2-fold increase in cell number could
account for a 10+-fold increase in cells that overexpress p53
in the 'high' vs the 'low' p53-expressing group. If clonal
expansion is not the cause of the normal high p53 expression
group, then this group is interesting but without explanation.
Our current hypothesis is that the members of the high
normal group are expressing high levels of (probably) wild-
type p53 owing to fast proliferation or accumulated DNA
damage from environmental carcinogen exposure.
Despite this subgroup oftumour-free patients who express-
ed p53 following cell culture, there was a significant differ-
ence in the mean percentage positive cells between tumour-
free and TCC normal urothelial cell cultures. This overex-
pression of p53 protein has not been previously described in
normal urothelium from patients with invasive TCC and
implicates p53 dysfunction in the early stages of carcino-
genesis in this disease. The association with icreased cell
growth suggests a consequent disturbance in control of cellu-
lar proliferation. A similar phenomenon was observed by
Farsund et al. (1984) when studying cell cycle distribution in
urothelium at sites distant from TCC, it was found that a
higher proportion of cells were in S or G2 when compared to
tumour-free patients. Since wild-type p53 inhibits cellular
growth (Sidransky et al., 1992), an abnormality in cell pro-
liferation, associated with aberrant p53 expression, is not
surprising. Our studies, however, cannot distinguish whether
this association is causal or incidental.
Such conformational variants of the protein have been
shown to bind p53-240 (Farsund et al., 1984). The nature of
the p53 protein detected by p53-240, following cell culture, is
uncertain. While the antibody is specific for the mutant form
in immunoprecipitation studies, immunohistochemical stain-
ing may detect stable, wild-type conformational variants
(Gannon et al., 1990). Stable, wild-type p53 protein has
recently been observed in normal cells of a cancer family
member without evidence of genetic mutation (Kern et al.,
1992). In addition, marrow blast cells from normal individ-
uals have been shown to express wild-type protein which is
identified by the p53-240 antibody (Ramel et al., 1992). The
abnormal expression of p53 seen on tissue culture may,
therefore, not necesarily reflect a genetic mutation.
Abnormal p53 expression is being increasingly recognised
in dysplastic, premalignant conditions. In Barrett's
oesophagus, increasing frequency of gene product expression
has been observed with increasing dysplasia (Bares et al.,
1992; Rivas et al., 1992; Kaklamani et al., 1993). We have
previously shown that, following cell culture, increased p53
protein is expressed in cells from adjacent normal mucosa in
oesophageal carcinoma (Mothersill et al., 1994). A similar
association between abnormal p53 expression and dysplasia
has been made in colonic adenomas; however, the protein
was observed in focal areas ofdysplasia rather than through-
out the adenoma (Kawasaki et al., 1992). The absence ofp53
in non-dysplastic areas of colorectal adenomas supports the
hypothesis that abnormlities in p53 occur in the transition
from adenoma to carcinoma and is thus a relatively late step
in carcinogenesis (Kawasaki et al., 1992). Our study shows
that abnormalities in p53 take place at an earlier stage in
urothehal carcinogenesis.
Histologically normal urothelial cells, at sites distant from
the tumour, were found to express the protein, implicating
p53 as part of a more generalised field change in patients
with invasive TCC. Expression of the protein was also
associated with increased cellular proliferation in vitro. These
findings suggest that aberrant p53 expression in normal
urothelium may be predictive of future carcinogenesis.p53
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